摘   要：目的  觀察厄貝沙坦聯(lián)合美托洛爾治療慢性充血性心衰的臨床療效。方法  選擇我院自2015年3月～2016年5月收治68例慢性充血性心衰患者作為研究對象，將其隨機分成對照組和研究組，每組34例。對照組采用厄貝沙坦治療，研究組采用厄貝沙坦聯(lián)合美托洛爾治療，比較兩組患者治療前后的心率（HR）、收縮壓（SBP）和舒張壓（DBP）等血壓水平以及左室舒張末內(nèi)徑（LVEDd）、左室收縮末內(nèi)徑（LVESd）和左室射血分數(shù)（LVEF）等左心功能指標，并統(tǒng)計和計算兩組患者治療期間的不良反應(yīng)發(fā)生率及治療的總有效率。結(jié)果  兩組患者治療前的心率、血壓及各項左心功能水平對比，差異均無統(tǒng)計學(xué)意義（P>0.05）。治療期間，研究組與對照組的不良反應(yīng)發(fā)生率對比差異統(tǒng)計學(xué)意義（P>0.05）。治療后，研究組的HR、DBP、DBP、LVEDd、LVESd均明顯低于對照組，研究組的LVEF、治療的總有效率明顯高于對照組，兩組對比差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論  對慢性充血性心衰患者采用厄貝沙坦聯(lián)合美托洛爾治療，不僅能有效改善患者的心率和血壓水平，同時還能有效促進患者的左心功能恢復(fù)，患者治療期間的毒副反應(yīng)發(fā)生率較低，因此其是一組安全、高效的組合治療藥物。
　　關(guān)鍵詞：厄貝沙坦;美托洛爾;慢性充血性心衰
　　中圖分類號：R541.6                                  文獻標識碼：A                                DOI：10.3969/j.issn.1006-1959.2018.05.044
　　文章編號：1006-1959（2018）05-0125-03
　　Efficacy of Irbesartan Combined with Metoprolol in the Treatment of Chronic Congestive Heart Failure
　　ZHANG Ting
　�。―epartment of Dry Diagnosis，157 Hospital，Shenyang 110045，Liaoning，China）
　　Abstract：Objective  To observe the clinical efficacy of irbesartan combined with metoprolol in the treatment of chronic congestive heart failure.Methods  68 patients with chronic congestive heart failure from March 2015 to May 2016 were randomly divided into control group（n=34）and study group（n=34）.The control group was treated with irbesartan and the study group with irbesartan combined with metoprolol.Before and after treatment，the blood pressure levels，such as heart rate（HR），systolic blood pressure（SBP）and diastolic blood pressure（DBP），left ventricular end-diastolic diameter（LVEDd），left ventricular end-systolic diameter （LVESd）and left ventricular ejection fraction（LVEF）were compared between the two groups.The incidence of adverse reactions during treatment and the total effective rate of treatment were counted and calculated.Results  There was no significant difference in heart rate，blood pressure and left ventricular function between the two groups before treatment（P>0.05）.During the treatment period，the incidence of adverse reactions in the study group and the control group was significantly different（P>0.05）.After treatment，the HR，DBP，DBP，LVEDd and LVESd in the study group were significantly lower than those in the control group.The total effective rate of LVEF and treatment in the study group was significantly higher than that in the control group，the difference between the two groups was statistically significant（P<0.05）.Conclusion  Irbesartan combined with metoprolol in patients with chronic congestive heart failure can not only improve the heart rate and blood pressure，but also promote the recovery of left ventricular function.The incidence of side effects during treatment is low，so it is a safe and effective combination of drugs.

相關(guān)熱詞搜索：心衰 療效 洛爾 觀察 治療慢性